GLP1R and early-onset autosomal dominant Alzheimer disease: <b>Background/Objective:</b> Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit neuroprotective properties in preclinical models of Alzheimer's disease (AD), reducing amyloid accumulation, neuroinflammation, and insulin resistance within the brain.